Notice Regarding the Recognition of Non-Operating Expenses and Revisions to Full-Year Earnings Forecast
株式会社イメージワン (the filing company). Related entities are Aristagora VC Israel Technology L.P. (the fund) and 株式会社Kaihan Medical
Assets held by Aristagora VC Israel Technology L.P. (the fund), loans to 株式会社Kaihan Medical, the Healthcare Solutions business, the Global Environmental Solutions business, visible and near-infrared spectroradiometers, and radiation-resistant cameras for the IAEA
The Company recognized a loss corresponding to its investment interest based on fluctuations in the valuation of assets held by the fund. It also conservatively assessed the collectability of loans after comprehensively considering 株式会社Kaihan Medical's financial position, operating results, cash flow position, ability to secure funds for repayment, and other factors. In addition, the causes included price adjustments due to higher procurement costs, system sales below plan, failure to win a major electronic medical records project, difficulty securing new projects and new orders, and a delay in the timing of modifications to radiation-resistant cameras for the IAEA.
The Company recognized a ¥53.263 million loss on investment partnership management and a ¥62.5 million provision for allowance for doubtful accounts as non-operating expenses. The full-year forecast was revised to net sales of ¥580 million, an operating loss of ¥736 million, an ordinary loss of ¥860 million, and a net loss of ¥728 million.
Cumulative third quarter of the fiscal year ending September 2026 (non-operating expenses); fiscal year ending September 2026 (earnings forecast)
Revised. Net sales were revised from the previous forecast of ¥1,377 million to ¥580 million, operating income from ¥76 million to an operating loss of ¥736 million, ordinary income from ¥74 million to an ordinary loss of ¥860 million, and net income from ¥226 million to a net loss of ¥728 million.
¥125 million (loans to 株式会社Kaihan Medical). A ¥62.5 million provision for allowance for doubtful accounts was recognized.
Actual results may differ from the forecast figures due to various factors in the future.
| Item | Details |
|---|---|
| Event name | Notice Regarding the Recognition of Non-Operating Expenses and Revisions to Full-Year Earnings Forecast |
| Date of occurrence | 30 June 2026 (date the loan to 株式会社Kaihan Medical was made); 12 August 2026 (date of the Board of Directors' resolution) |
| Subject Entity | 株式会社イメージワン (the filing company). Related entities are Aristagora VC Israel Technology L.P. (the fund) and 株式会社Kaihan Medical |
| Target Locations / Products | Assets held by Aristagora VC Israel Technology L.P. (the fund), loans to 株式会社Kaihan Medical, the Healthcare Solutions business, the Global Environmental Solutions business, visible and near-infrared spectroradiometers, and radiation-resistant cameras for the IAEA |
| Cause | The Company recognized a loss corresponding to its investment interest based on fluctuations in the valuation of assets held by the fund. It also conservatively assessed the collectability of loans after comprehensively considering 株式会社Kaihan Medical's financial position, operating results, cash flow position, ability to secure funds for repayment, and other factors. In addition, the causes included price adjustments due to higher procurement costs, system sales below plan, failure to win a major electronic medical records project, difficulty securing new projects and new orders, and a delay in the timing of modifications to radiation-resistant cameras for the IAEA. |
| Amount of Impact on Business Performance | The Company recognized a ¥53.263 million loss on investment partnership management and a ¥62.5 million provision for allowance for doubtful accounts as non-operating expenses. The full-year forecast was revised to net sales of ¥580 million, an operating loss of ¥736 million, an ordinary loss of ¥860 million, and a net loss of ¥728 million. |
| Accounting period in which recognized | Cumulative third quarter of the fiscal year ending September 2026 (non-operating expenses); fiscal year ending September 2026 (earnings forecast) |
| Impact on Earnings Forecast | Revised. Net sales were revised from the previous forecast of ¥1,377 million to ¥580 million, operating income from ¥76 million to an operating loss of ¥736 million, ordinary income from ¥74 million to an ordinary loss of ¥860 million, and net income from ¥226 million to a net loss of ¥728 million. |
| Amount of receivables at risk of non-collection or delayed collection | ¥125 million (loans to 株式会社Kaihan Medical). A ¥62.5 million provision for allowance for doubtful accounts was recognized. |
| Outlook | Actual results may differ from the forecast figures due to various factors in the future. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Healthcare Solutions business, the reasons were price adjustments due to higher procurement costs, failure to meet the system sales plan, and failure to win a major electronic medical records project. In the Global Environmental Solutions business, the reasons were difficulty securing new projects, failure to obtain new orders for visible and near-infrared spectroradiometers, and a delay in the timing of modifications to radiation-resistant cameras for the IAEA. In addition, the Company recognized non-operating expenses based on fluctuations in the valuation of assets held by the fund and a conservative assessment of the collectability of loans, taking into account 株式会社Kaihan Medical's financial position, operating results, cash flow position, and ability to secure funds for repayment.